NEW YORK, October 11, 2017 /PRNewswire/ --
If you want a Stock Review on EPZM, FGEN, GBT, or ICPT then come overto http://dailystocktracker.com/register/ and sign up for your free customized report. On Tuesday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.11%; the Dow Jones Industrial Average edged 0.31%
Cambridge, Massachusetts headquartered Epizyme Inc.'s stock finished Tuesday's session 0.28% lower at $17.95. A total volume of 360,191 shares was traded. The Company's shares have advanced 21.69% over the previous three months, 84.48% in the last twelve months, and 48.35% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 10.90% and 22.74%, respectively. Furthermore, shares of Epizyme, which discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the US, have a Relative Strength Index (RSI) of 53.08.
On September 20th, 2017, research firm Jefferies initiated a 'Buy' rating on the Company's stock, with a target price of $23 per share. The free research report on EPZM is available at:
Shares in San Francisco, California headquartered FibroGen Inc. ended at $55.15, up 0.09% from the last trading session. The stock recorded a trading volume of 554,519 shares. The Company's shares have gained 10.52% in the last one month, 65.37% over the previous three months, 172.35% in the last twelve months, and 157.71% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 17.53% and 72.76%, respectively. Moreover, shares of FibroGen, which discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the US, have an RSI of 59.79. The complimentary report on FGEN can be downloaded at:
Global Blood Therapeutics
South San Francisco, California headquartered Global Blood Therapeutics Inc.'s stock ended yesterday's session 3.78% higher at $32.95 with a total trading volume of 671,552 shares. The Company's shares have advanced 19.38% in the past month, 16.43% over the previous three months, 77.15% in the last twelve months, and 128.03% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 15.97% and 20.18%, respectively. Additionally, shares of Global Blood Therapeutics, which engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders, have an RSI of 65.87.
On September 21st, 2017, research firm Needham initiated a 'Buy' rating on the Company's stock, with a target price of $51 per share. Visit us today and download our complete research report on GBT for free at:
On Tuesday, shares in Intercept Pharmaceuticals Inc. recorded a trading volume of 718,125 shares. The stock finished the day 0.81% lower at $68.63. The stock is trading below its 50-day moving average by 28.29%. Furthermore, shares of Intercept Pharma, which focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases, have an RSI of 37.99.
On October 06th, 2017, research firm Goldman resumed its 'Neutral' rating on the Company's stock. Get free access to your technical report on ICPT at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All